NASDAQ:XENE - CA98420N1050 - Common Stock
The current stock price of XENE is 38.64 USD. In the past month the price increased by 12.75%. In the past year, price increased by 0.44%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 20.11 | 376.28B | ||
AMGN | AMGEN INC | 12.84 | 150.79B | ||
GILD | GILEAD SCIENCES INC | 14.57 | 139.93B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 23.43 | 101.77B | ||
REGN | REGENERON PHARMACEUTICALS | 12.43 | 60.12B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.45B | ||
ARGX | ARGENX SE - ADR | 79.14 | 44.90B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.42 | 37.89B | ||
INSM | INSMED INC | N/A | 30.13B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.88B | ||
NTRA | NATERA INC | N/A | 22.86B | ||
BIIB | BIOGEN INC | 8.74 | 20.52B |
Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 316 full-time employees. The company went IPO on 2014-10-17. The firm is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the advanced, clinically validated potassium channel modulator in late-stage clinical development for the treatment of multiple indications that include epilepsy, including focal onset seizures (FOS), and primary generalized tonic-clonic seizures (PGTCS), as well as neuropsychiatric disorders including major depressive disorder (MDD), and bipolar depression (BPD). The firm is evaluating multiple therapeutic candidates targeting Kv7, Nav1.7, and Nav1.1 across various indications.
XENON PHARMACEUTICALS INC
3650 Gilmore Way
Vancouver BRITISH COLUMBIA V5G 48W CA
CEO: Simon Pimstone
Employees: 316
Phone: 16044843300
The current stock price of XENE is 38.64 USD. The price decreased by -0.49% in the last trading session.
The exchange symbol of XENON PHARMACEUTICALS INC is XENE and it is listed on the Nasdaq exchange.
XENE stock is listed on the Nasdaq exchange.
25 analysts have analysed XENE and the average price target is 55.35 USD. This implies a price increase of 43.25% is expected in the next year compared to the current price of 38.64. Check the XENON PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
XENON PHARMACEUTICALS INC (XENE) has a market capitalization of 2.98B USD. This makes XENE a Mid Cap stock.
XENON PHARMACEUTICALS INC (XENE) currently has 316 employees.
XENON PHARMACEUTICALS INC (XENE) has a support level at 38.63 and a resistance level at 38.68. Check the full technical report for a detailed analysis of XENE support and resistance levels.
The Revenue of XENON PHARMACEUTICALS INC (XENE) is expected to grow by 2419.98% in the next year. Check the estimates tab for more information on the XENE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
XENE does not pay a dividend.
XENON PHARMACEUTICALS INC (XENE) will report earnings on 2025-11-10, after the market close.
XENON PHARMACEUTICALS INC (XENE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.55).
The outstanding short interest for XENON PHARMACEUTICALS INC (XENE) is 9.13% of its float. Check the ownership tab for more information on the XENE short interest.
ChartMill assigns a technical rating of 8 / 10 to XENE. When comparing the yearly performance of all stocks, XENE turns out to be only a medium performer in the overall market: it outperformed 65.09% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to XENE. No worries on liquidiy or solvency for XENE as it has an excellent financial health rating, but there are worries on the profitability.
Over the last trailing twelve months XENE reported a non-GAAP Earnings per Share(EPS) of -3.55. The EPS decreased by -29.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -41.26% | ||
ROE | -43.89% | ||
Debt/Equity | 0 |
25 analysts have analysed XENE and the average price target is 55.35 USD. This implies a price increase of 43.25% is expected in the next year compared to the current price of 38.64.
For the next year, analysts expect an EPS growth of -42% and a revenue growth 2419.98% for XENE